CD33 and acute myeloid leukemia: Furthermore, CD33-CAR-NK cells effectively eliminated all bone marrow- and spleen-engrafted, as well as the majority of peripheral AML cells in an OCI-AML2 xenograft mouse model without detectable side effects.